BPC
CLDX icon

Bryce Point Capital’s Celldex Therapeutics CLDX Stock Holding History

Bryce Point Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,265
Closed -$351K – 195
2025
Q1 		$351K Sell
16,265
-7,525
-32% -$168K 0.26% 157
2024
Q4 		$601K Buy
+23,790
New +$646K 0.17% 162

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bryce Point Capital's CLDX Position: Q2 2025 in Review

Bryce Point Capital sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 16,265 shares — an estimated $351K sold.

Bryce Point Capital first reported a position in CLDX in Q4 2024 and held it in 2 quarters. The position peaked at $601K in Q4 2024. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Bryce Point Capital reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bryce Point Capital sold 16,265 Celldex Therapeutics shares in Q2 2025, an estimated $351K.
  • Bryce Point Capital first reported a position in Celldex Therapeutics in Q4 2024 and held it in 2 quarters.
  • Bryce Point Capital's Celldex Therapeutics position peaked at $601K in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Bryce Point Capital's 13F filing for Q2 2025, filed 5 Aug 2025.